SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "L773:1474 547X "

form:Search_simp_t: L773:1474 547X

  • navigation:Result_t 1-10 navigation:of_t 902
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  •  
2.
  • Abbara, Aula, et al. (creator_code:aut_t)
  • Weaponisation of water
  • 2022
  • record:In_t: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 400:10367, s. 1925-1925
  • swepub:Mat_article_t (swepub:level_refereed_t)
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Abe, O, et al. (creator_code:aut_t)
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  • 2005
  • record:In_t: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
  •  
8.
  •  
9.
  •  
10.
  • Afshin, Ashkan, et al. (creator_code:aut_t)
  • Health effects of dietary risks in 195 countries, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017
  • 2019
  • record:In_t: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 393:10184, s. 1958-1972
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background: Suboptimal diet is an important preventable risk factor for non-communicable diseases (NCDs); however, its impact on the burden of NCDs has not been systematically evaluated. This study aimed to evaluate the consumption of major foods and nutrients across 195 countries and to quantify the impact of their suboptimal intake on NCD mortality and morbidity.Methods: By use of a comparative risk assessment approach, we estimated the proportion of disease-specific burden attributable to each dietary risk factor (also referred to as population attributable fraction) among adults aged 25 years or older. The main inputs to this analysis included the intake of each dietary factor, the effect size of the dietary factor on disease endpoint, and the level of intake associated with the lowest risk of mortality. Then, by use of diseasespecific population attributable fractions, mortality, and disability-adjusted life-years (DALYs), we calculated the number of deaths and DALYs attributable to diet for each disease outcome.Findings: In 2017, 11 million (95% uncertainty interval [UI] 10-12) deaths and 255 million (234-274) DALYs were attributable to dietary risk factors. High intake of sodium (3 million [1-5] deaths and 70 million [34-118] DALYs), low intake of whole grains (3 million [2-4] deaths and 82 million [59-109] DALYs), and low intake of fruits (2 million [1-4] deaths and 65 million [41-92] DALYs) were the leading dietary risk factors for deaths and DALYs globally and in many countries. Dietary data were from mixed sources and were not available for all countries, increasing the statistical uncertainty of our estimates.Interpretation: This study provides a comprehensive picture of the potential impact of suboptimal diet on NCD mortality and morbidity, highlighting the need for improving diet across nations. Our findings will inform implementation of evidence-based dietary interventions and provide a platform for evaluation of their impact on human health annually.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-10 navigation:of_t 902
swepub:Mat_t
swepub:mat_article_t (860)
swepub:mat_researchreview_t (32)
swepub:mat_conferencepaper_t (7)
swepub:mat_publicationother_t (3)
swepub:Level_t
swepub:level_refereed_t (747)
swepub:level_scientificother_t (152)
swepub:level_popularscientific_t (3)
swepub:Hitlist_author_t
Gupta, R. (40)
Malekzadeh, R (39)
Dandona, L (37)
Naghavi, M (37)
Farzadfar, F (36)
Dandona, R (35)
deldatabas:search_more_t
Fischer, F (35)
Jonas, JB (33)
Monasta, L (33)
Larsson, Anders (31)
Nangia, V (31)
Remuzzi, G (31)
Shiri, R (31)
Alvis-Guzman, N (30)
Koyanagi, A (30)
Majeed, A (30)
Mohammed, S (30)
Mokdad, AH (30)
Shibuya, K (30)
Venketasubramanian, ... (30)
Bikbov, B (29)
Hafezi-Nejad, N (29)
Kosen, S (29)
Lozano, R (29)
Topor-Madry, R (29)
Hamidi, S (28)
Meretoja, A (28)
Moradi-Lakeh, M (28)
Perico, N (28)
Ronfani, L (28)
Karch, A (27)
Leigh, J (27)
Sepanlou, SG (27)
Singh, JA (27)
Abd-Allah, F (26)
Alam, K (26)
Kabir, Z (26)
Lalloo, R (26)
Mckee, M (26)
Mendoza, W (26)
Pesudovs, K (26)
Basu, S (25)
Bhutta, ZA (25)
Brenner, H (25)
Hay, SI (25)
Jha, V (25)
Kumar, GA (25)
Lopez, AD (25)
Radfar, A (25)
Rawaf, S (25)
deldatabas:search_less_t
swepub:Hitlist_uni_t
swepub_uni:ki_t (438)
swepub_uni:uu_t (168)
swepub_uni:lu_t (131)
swepub_uni:umu_t (116)
swepub_uni:gu_t (89)
swepub_uni:liu_t (52)
deldatabas:search_more_t
swepub_uni:oru_t (24)
swepub_uni:su_t (20)
swepub_uni:du_t (12)
swepub_uni:cth_t (11)
swepub_uni:miun_t (10)
swepub_uni:sh_t (6)
swepub_uni:his_t (4)
swepub_uni:kau_t (4)
swepub_uni:kth_t (3)
swepub_uni:ltu_t (3)
swepub_uni:mdh_t (3)
swepub_uni:hb_t (3)
swepub_uni:hj_t (2)
swepub_uni:lnu_t (2)
swepub_uni:shh_t (2)
swepub_uni:hig_t (1)
swepub_uni:mau_t (1)
swepub_uni:bth_t (1)
swepub_uni:esh_t (1)
swepub_uni:rkh_t (1)
deldatabas:search_less_t
hitlist:Language_t
language:Eng_t (902)
hitlist:HSV_t
hsv:Cat_3_t (381)
hsv:Cat_5_t (14)
hsv:Cat_1_t (4)
hsv:Cat_2_t (1)
hsv:Cat_4_t (1)
hsv:Cat_6_t (1)

hitlist:Year_t

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t